Reduce the need for opioids while providing long-lasting postsurgical pain control…all from a single doseLearn More about EXPAREL
With a unique drug delivery system, EXPAREL is designed to extend postsurgical analgesiaLearn More about DepoFoam
The clinical benefit of the attendant decrease in opioid consumption was not demonstrated.
EXPAREL (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
If You Are a Patient
Visit the EXPAREL Patient Site for resources to help before and after surgery.More
Is EXPAREL Right for My Patients?
Learn the types of patients and procedures that may benefit from EXPAREL.More
Video About DepoFoam®
Watch this short animation to see how EXPAREL uses DepoFoam.View
This site is for informational purposes only and is intended to address medical questions from healthcare professionals in the United States.To report an adverse event, e-mail firstname.lastname@example.org or dial 1-855-RX-EXPAREL (1-855-793-9727).
For medical inquiries related to EXPAREL, submit a request to Medical Information or call 1-855-RX-EXPAREL (1-855-793-9727).
These are not all of the potential important safety considerations for EXPAREL; please see the full Prescribing Information.
EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia.
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.
Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL.
Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.
In clinical trials, the most common adverse reactions (incidence =10%) following EXPAREL administration were nausea, constipation, and vomiting.
Studies demonstrating the safety and efficacy of EXPAREL were conducted in hemorrhoidectomy and bunionectomy; EXPAREL has not been demonstrated to be safe and effective in other procedures
Non-US healthcare professionals can submit a request to email@example.com
If you are not a healthcare professional, please discuss any questions you have regarding your health or treatment with your physician, pharmacist, nurse, or other healthcare professional.
Sign up to receive updates on EXPAREL.